Alnylam Pharmaceuticals (ALNY) Short term Debt (2024 - 2025)
Alnylam Pharmaceuticals posted quarterly Short term Debt of $121.3 million for Q3 2025, little changed on a QoQ basis from $120.8 million in Q2 2025.
Alnylam Pharmaceuticals (ALNY) has 2 years of Short term Debt data on file, last reported at $121.3 million in Q3 2025.
- For the quarter ending Q3 2025, Short term Debt changed N/A year-over-year to $121.3 million; the trailing twelve-month figure through Sep 2025 stood at $121.3 million (changed N/A YoY), and the FY2024 full-year result was $93.8 million, changed N/A from the prior year.
- Short term Debt for Q3 2025 stood at $121.3 million, roughly flat from $120.8 million in the prior quarter.
- Across five years, Short term Debt topped out at $121.3 million in Q3 2025 and bottomed at $93.8 million in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 121.30 Mn |
| Jun 30, 2025 | 120.80 Mn |
| Mar 31, 2025 | 118.10 Mn |
| Dec 31, 2024 | 93.80 Mn |